Vertical Group

MicroTransponder, Inc. is a medical device company based in Austin, Texas, specializing in the development and commercialization of neurostimulation devices aimed at treating neurological disorders. Founded in 2007, the company focuses on therapies that utilize vagus nerve stimulation to address conditions such as tinnitus, chronic pain, and rehabilitation following strokes. Its flagship product, Vivistim, has received FDA approval for use in ischemic stroke survivors experiencing moderate to severe upper limb impairment. MicroTransponder's innovative approaches, which include paired vagus nerve stimulation and wireless neurostimulation systems, are designed to enhance recovery and improve quality of life for patients facing various neurological challenges.

Route 92 Medical is a medical device company founded in 2015 and based in San Mateo, California. The company specializes in developing innovative solutions for stroke treatment, focusing on a stealthy catheter designed for acute ischemic stroke. Their technology includes a percutaneous catheter, a rapid aspiration thrombectomy system, and an intra-cerebral implant delivery mechanism. These advancements aim to assist healthcare professionals in effectively treating stroke patients and enhancing their recovery outcomes.

Luminopia is focused on developing innovative treatments for significant neuro-visual disorders, particularly amblyopia, commonly known as lazy eye, which is a leading cause of vision loss in children. The company is creating digital therapeutics that undergo rigorous evaluation for FDA approval while ensuring they are engaging for patients. In collaboration with Boston Children's Hospital, Luminopia is advancing its primary product, Luminopia One, which utilizes a binocular therapeutic approach to effectively address amblyopia. This development aims to enhance the capabilities of healthcare professionals in treating these critical vision disorders.

Luminopia is focused on developing innovative treatments for significant neuro-visual disorders, particularly amblyopia, commonly known as lazy eye, which is a leading cause of vision loss in children. The company is creating digital therapeutics that undergo rigorous evaluation for FDA approval while ensuring they are engaging for patients. In collaboration with Boston Children's Hospital, Luminopia is advancing its primary product, Luminopia One, which utilizes a binocular therapeutic approach to effectively address amblyopia. This development aims to enhance the capabilities of healthcare professionals in treating these critical vision disorders.

MicroTransponder, Inc. is a medical device company based in Austin, Texas, specializing in the development and commercialization of neurostimulation devices aimed at treating neurological disorders. Founded in 2007, the company focuses on therapies that utilize vagus nerve stimulation to address conditions such as tinnitus, chronic pain, and rehabilitation following strokes. Its flagship product, Vivistim, has received FDA approval for use in ischemic stroke survivors experiencing moderate to severe upper limb impairment. MicroTransponder's innovative approaches, which include paired vagus nerve stimulation and wireless neurostimulation systems, are designed to enhance recovery and improve quality of life for patients facing various neurological challenges.

Carlsmed is a medical technology company based in San Diego, California, specializing in spine surgery solutions. Founded in 2018, the company has developed the aprevo™ implant system, which is the first surgical implant designated as a breakthrough technology by the FDA. This innovative 3-D printed implant system offers personalized medicine benefits specifically for lumbar fusion surgery. Carlsmed employs machine learning technologies and analysis of prior outcomes data to enhance the treatment of complex adult spinal deformities, aiming to improve surgical outcomes and reduce healthcare costs associated with spine surgery. The company serves hospitals and surgeons nationwide, providing advanced solutions for adult spinal malalignment.

Route 92 Medical is a medical device company founded in 2015 and based in San Mateo, California. The company specializes in developing innovative solutions for stroke treatment, focusing on a stealthy catheter designed for acute ischemic stroke. Their technology includes a percutaneous catheter, a rapid aspiration thrombectomy system, and an intra-cerebral implant delivery mechanism. These advancements aim to assist healthcare professionals in effectively treating stroke patients and enhancing their recovery outcomes.

Carlsmed is a medical technology company based in San Diego, California, specializing in spine surgery solutions. Founded in 2018, the company has developed the aprevo™ implant system, which is the first surgical implant designated as a breakthrough technology by the FDA. This innovative 3-D printed implant system offers personalized medicine benefits specifically for lumbar fusion surgery. Carlsmed employs machine learning technologies and analysis of prior outcomes data to enhance the treatment of complex adult spinal deformities, aiming to improve surgical outcomes and reduce healthcare costs associated with spine surgery. The company serves hospitals and surgeons nationwide, providing advanced solutions for adult spinal malalignment.

Biorez, Inc. is a medical device company specializing in the development of bioresorbable scaffold implants aimed at regenerating functional tissue in vivo. Founded in 2008 and based in New Haven, Connecticut, Biorez offers innovative products such as an off-the-shelf implant for anterior cruciate ligament (ACL) reconstruction, which eliminates the need for harvesting donor tissue and serves as a superior alternative to cadaver-based materials. The company's technology utilizes a degradable polymer, specifically PLLA, to create implants that stabilize surgical repairs and facilitate the body's natural tissue regeneration, thereby enhancing musculoskeletal outcomes. Among its product lineup is the L-C Ligament® and the biorez GRAFT™, an FDA-cleared device designed for soft tissue augmentation of the rotator cuff. By leveraging this technology, Biorez aims to accelerate patient recovery and improve surgical outcomes in orthopedic procedures.

Biorez, Inc. is a medical device company specializing in the development of bioresorbable scaffold implants aimed at regenerating functional tissue in vivo. Founded in 2008 and based in New Haven, Connecticut, Biorez offers innovative products such as an off-the-shelf implant for anterior cruciate ligament (ACL) reconstruction, which eliminates the need for harvesting donor tissue and serves as a superior alternative to cadaver-based materials. The company's technology utilizes a degradable polymer, specifically PLLA, to create implants that stabilize surgical repairs and facilitate the body's natural tissue regeneration, thereby enhancing musculoskeletal outcomes. Among its product lineup is the L-C Ligament® and the biorez GRAFT™, an FDA-cleared device designed for soft tissue augmentation of the rotator cuff. By leveraging this technology, Biorez aims to accelerate patient recovery and improve surgical outcomes in orthopedic procedures.

Hinge Health is a digital healthcare company focused on treating musculoskeletal disorders, particularly back and joint pain, through innovative technology. Founded in 2015 and headquartered in San Francisco, the company offers a range of solutions including wearable sensors, a user-friendly application, and access to a network of physical therapists and health coaches. These tools are designed to provide personalized care and facilitate recovery while addressing the limitations of traditional physical therapy, such as high costs and accessibility issues. By combining wearable technology with expert medical support, Hinge Health aims to empower individuals to manage their pain effectively and reduce reliance on opioids and surgical interventions. The company's services are utilized by both individuals and businesses, making high-quality care more accessible to a broader audience.

Outset Medical, Inc. is a medical technology company based in San Jose, California, focused on innovating hemodialysis systems. The company has developed Tablo, a compact dialysis machine designed for use in both acute and chronic care settings. This system integrates essential features such as water purification, on-demand dialysate production, and advanced software capabilities, including wireless data connectivity and sensor-based automation. By simplifying the dialysis process, Tablo aims to reduce costs and enhance the experience for both patients and healthcare providers. Founded in 2003 and originally named Home Dialysis Plus, Ltd., Outset Medical rebranded in 2015 to reflect its commitment to transforming dialysis care.

Hinge Health is a digital healthcare company focused on treating musculoskeletal disorders, particularly back and joint pain, through innovative technology. Founded in 2015 and headquartered in San Francisco, the company offers a range of solutions including wearable sensors, a user-friendly application, and access to a network of physical therapists and health coaches. These tools are designed to provide personalized care and facilitate recovery while addressing the limitations of traditional physical therapy, such as high costs and accessibility issues. By combining wearable technology with expert medical support, Hinge Health aims to empower individuals to manage their pain effectively and reduce reliance on opioids and surgical interventions. The company's services are utilized by both individuals and businesses, making high-quality care more accessible to a broader audience.

Route 92 Medical is a medical device company founded in 2015 and based in San Mateo, California. The company specializes in developing innovative solutions for stroke treatment, focusing on a stealthy catheter designed for acute ischemic stroke. Their technology includes a percutaneous catheter, a rapid aspiration thrombectomy system, and an intra-cerebral implant delivery mechanism. These advancements aim to assist healthcare professionals in effectively treating stroke patients and enhancing their recovery outcomes.

Suture Concepts provides solutions for physicians who practice in a cost-conscious environment. They also provide solutions for securing soft tissue to other tissues, the bone, or medical devices.

Silk Road Medical, Inc. is a medical device company based in Sunnyvale, California, specializing in the treatment of carotid artery disease through its innovative transcarotid artery revascularization (TCAR) approach. Founded in 2007, the company develops and manufactures minimally invasive devices aimed at reducing the risk of stroke and improving patient outcomes. Its product portfolio includes the ENROUTE Transcarotid Neuroprotection System, which facilitates direct access to the common carotid artery while ensuring temporary blood flow reversal to protect the brain, and the ENROUTE Transcarotid Stent System, a self-expanding stent supported by clinical data on safety outcomes. Additionally, the ENHANCE Transcarotid Peripheral Access Kit and the ENROUTE 0.014 Guidewire are designed to aid in gaining access and delivering interventional devices effectively. Silk Road Medical aims to establish TCAR as the standard of care for carotid artery disease treatment.

Outset Medical, Inc. is a medical technology company based in San Jose, California, focused on innovating hemodialysis systems. The company has developed Tablo, a compact dialysis machine designed for use in both acute and chronic care settings. This system integrates essential features such as water purification, on-demand dialysate production, and advanced software capabilities, including wireless data connectivity and sensor-based automation. By simplifying the dialysis process, Tablo aims to reduce costs and enhance the experience for both patients and healthcare providers. Founded in 2003 and originally named Home Dialysis Plus, Ltd., Outset Medical rebranded in 2015 to reflect its commitment to transforming dialysis care.

Outset Medical, Inc. is a medical technology company based in San Jose, California, focused on innovating hemodialysis systems. The company has developed Tablo, a compact dialysis machine designed for use in both acute and chronic care settings. This system integrates essential features such as water purification, on-demand dialysate production, and advanced software capabilities, including wireless data connectivity and sensor-based automation. By simplifying the dialysis process, Tablo aims to reduce costs and enhance the experience for both patients and healthcare providers. Founded in 2003 and originally named Home Dialysis Plus, Ltd., Outset Medical rebranded in 2015 to reflect its commitment to transforming dialysis care.

Suture Concepts provides solutions for physicians who practice in a cost-conscious environment. They also provide solutions for securing soft tissue to other tissues, the bone, or medical devices.

Monteris Medical, Inc. is a medical device company that specializes in developing and marketing technologies for minimally invasive neurosurgery, particularly focused on the treatment of brain lesions. The company's flagship product, the NeuroBlate System, is a laser thermotherapy system designed for the volumetric ablation of pathological brain lesions, including both primary and metastatic tumors. This system utilizes magnetic resonance imaging (MRI) guidance and applies focused laser energy to effectively target and ablate tumors while minimizing damage to surrounding healthy tissue. Monteris Medical also offers various stereotactic anchoring devices for precise image-guided trajectory alignment, as well as stabilization systems for MRI-based procedures that require head fixation. Founded in 1999 and headquartered in Plymouth, Minnesota, the company serves neurosurgeons across the United States through a dedicated sales force. Monteris Medical was previously known as AutoLITT until rebranding in 2003.

Omada Health, Inc. is a digital healthcare company that creates and implements online programs aimed at managing chronic conditions. Founded in 2011 and headquartered in San Francisco, with an additional office in Atlanta, Omada Health focuses on helping employers and health plans identify individuals at risk for preventable chronic diseases such as prediabetes, diabetes, hypertension, and heart disease. The company offers personalized programs that adapt to the unique needs of participants, incorporating professional health coaching, connected health devices, and real-time data to foster sustainable lifestyle changes. Omada Health is recognized as the largest provider of the National Diabetes Prevention Program, delivering clinically effective solutions that empower individuals to take charge of their health and achieve their wellness goals.

Omada Health, Inc. is a digital healthcare company that creates and implements online programs aimed at managing chronic conditions. Founded in 2011 and headquartered in San Francisco, with an additional office in Atlanta, Omada Health focuses on helping employers and health plans identify individuals at risk for preventable chronic diseases such as prediabetes, diabetes, hypertension, and heart disease. The company offers personalized programs that adapt to the unique needs of participants, incorporating professional health coaching, connected health devices, and real-time data to foster sustainable lifestyle changes. Omada Health is recognized as the largest provider of the National Diabetes Prevention Program, delivering clinically effective solutions that empower individuals to take charge of their health and achieve their wellness goals.

Silk Road Medical, Inc. is a medical device company based in Sunnyvale, California, specializing in the treatment of carotid artery disease through its innovative transcarotid artery revascularization (TCAR) approach. Founded in 2007, the company develops and manufactures minimally invasive devices aimed at reducing the risk of stroke and improving patient outcomes. Its product portfolio includes the ENROUTE Transcarotid Neuroprotection System, which facilitates direct access to the common carotid artery while ensuring temporary blood flow reversal to protect the brain, and the ENROUTE Transcarotid Stent System, a self-expanding stent supported by clinical data on safety outcomes. Additionally, the ENHANCE Transcarotid Peripheral Access Kit and the ENROUTE 0.014 Guidewire are designed to aid in gaining access and delivering interventional devices effectively. Silk Road Medical aims to establish TCAR as the standard of care for carotid artery disease treatment.

AtheroMed, Inc. is a medical device company based in Menlo Park, California, founded in 2006. The company specializes in developing catheter-based treatments for peripheral arterial disease (PAD). Its innovative system is designed to accommodate a range of vessel diameters, from small vessels at the ankle to larger vessels above the knee, thereby enhancing treatment options for patients suffering from this condition.

Flexuspine is a spinal device company based in Pittsburgh, Pennsylvania, founded in 2003. It specializes in developing innovative spinal segment replacements designed as an alternative to traditional lumbar fusion surgeries. The company's primary offering is a functional spinal unit that combines an interbody disc component with a posterior dynamic resistance component, effectively restoring mobility to affected segments of the lumbar spine. This technology aims to enhance the overall functionality of the spine for patients following surgery, providing a comprehensive solution to spinal issues.

Suture Concepts provides solutions for physicians who practice in a cost-conscious environment. They also provide solutions for securing soft tissue to other tissues, the bone, or medical devices.

TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that discovers and develops small molecule drugs that modulate programmed cell death pathways to treat debilitating diseases and conditions. The company's Smac Mimetics neutralize critical blocks in the apoptosis pathway to selectively destroy cancer cells. Its Necrostatin drugs block critical steps in the process leading to necrosis, enabling cell survival in a wide range of diseases and injuries where necrosis is a critical component of pathology.

ProteinSimple, part of the Protein Platforms division of Bio-Techne, specializes in innovative protein analysis tools that assist researchers in understanding proteins and their roles in disease. The company offers a diverse range of products, including immunoassay systems for quantifying protein expression and systems designed to assess the structure and purity of protein-based therapeutics. Their nano-proteomic analysis systems focus on resolving protein analysis issues, enabling life science researchers to measure phosphor-protein signaling and activation in small biological samples. These tools allow for the quantification of phosphor-protein isoforms in various cell types, including primary and sorted stem cells, and facilitate the monitoring of drug actions in tissue sections and fine needle aspirates. ProteinSimple's solutions are vital for advancing research in the life sciences globally.

TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that discovers and develops small molecule drugs that modulate programmed cell death pathways to treat debilitating diseases and conditions. The company's Smac Mimetics neutralize critical blocks in the apoptosis pathway to selectively destroy cancer cells. Its Necrostatin drugs block critical steps in the process leading to necrosis, enabling cell survival in a wide range of diseases and injuries where necrosis is a critical component of pathology.

PhotoThera is currently hiring for the following positions: Sr. Software Engineer Mechanical Engineer Configuration Management Engineer Sr. Electrical Engineer Send your resume and cover letter to ktitano@photothera.com, or go to www.photothera.com for further information. Specialties laser, medical device, eschemic, stroke, infrared

ProteinSimple, part of the Protein Platforms division of Bio-Techne, specializes in innovative protein analysis tools that assist researchers in understanding proteins and their roles in disease. The company offers a diverse range of products, including immunoassay systems for quantifying protein expression and systems designed to assess the structure and purity of protein-based therapeutics. Their nano-proteomic analysis systems focus on resolving protein analysis issues, enabling life science researchers to measure phosphor-protein signaling and activation in small biological samples. These tools allow for the quantification of phosphor-protein isoforms in various cell types, including primary and sorted stem cells, and facilitate the monitoring of drug actions in tissue sections and fine needle aspirates. ProteinSimple's solutions are vital for advancing research in the life sciences globally.

OncoMed Pharmaceuticals is a clinical-stage biopharmaceutical company based in Redwood City, California, specializing in the discovery and development of innovative therapeutics aimed at addressing the biological mechanisms that drive cancer growth, resistance, recurrence, and metastasis. The company is advancing several therapeutic candidates, including Navicixizumab, a bispecific monoclonal antibody targeting Delta-like ligand 4 and vascular endothelial growth factor, which has completed early-phase clinical trials for various solid tumors. Another key candidate, Etigilimab, is an anti-TIGIT monoclonal antibody currently undergoing Phase Ia/b clinical trials for advanced or metastatic solid tumors. OncoMed is also engaged in strategic partnerships aimed at the development of novel small molecule therapeutics and biologics targeting cancer stem cells and the Wnt signaling pathway. Founded in 2004, OncoMed Pharmaceuticals operates as a subsidiary of Mereo BioPharma Group plc.

ForteBio is a venture-capital funded life science company developing analytical systems to provide rapid, real-time results for protein quantification or characterization of protein-protein interaction. These systems enable real-time analysis of biomolecular interactions in micro-volume sample sizes, providing information on affinity, kinetics, and concentration.

Onyx Pharmaceuticals (NASDAQ: ONXX) is a biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer and other serious diseases.

Meritage Pharma, Inc. develops prescription products for the treatment of gastrointestinal and atopic diseases. It offers budesonide, an active pharmaceutical ingredient and a glucocorticoid steroid for products that treat pediatric asthma, allergic rhinitis, and Crohn’s disease; and oral budesonide suspension, an oral formulation of budesonide for the potential treatment of adolescents and young adults with eosinophilic esophagitis, an allergic inflammation of the gastrointestinal tract. Meritage Pharma, Inc. was founded in 2008 and is based in San Diego, California.

Tepha, Inc. is a medical device company based in Lexington, Massachusetts, specializing in the development and manufacturing of medical device components utilizing proprietary biomaterial technology. Founded in 1998, the company focuses on absorbable biomaterials derived from polyhydroxyalkanoates (PHAs), engineered through recombinant DNA technology. Tepha's product offerings include monofilament sutures for soft tissue approximation, monofilament meshes for various surgical applications including hernia and prolapse repairs, and P4HB regenerative polymer scaffolds for treating stress urinary incontinence. Additionally, the company produces surgical films and composite meshes designed to enhance tissue support and minimize attachment. Tepha's innovative materials are characterized by their flexibility, elasticity, biocompatibility, and excellent tensile strength, addressing unmet needs across multiple medical fields.

Silk Road Medical, Inc. is a medical device company based in Sunnyvale, California, specializing in the treatment of carotid artery disease through its innovative transcarotid artery revascularization (TCAR) approach. Founded in 2007, the company develops and manufactures minimally invasive devices aimed at reducing the risk of stroke and improving patient outcomes. Its product portfolio includes the ENROUTE Transcarotid Neuroprotection System, which facilitates direct access to the common carotid artery while ensuring temporary blood flow reversal to protect the brain, and the ENROUTE Transcarotid Stent System, a self-expanding stent supported by clinical data on safety outcomes. Additionally, the ENHANCE Transcarotid Peripheral Access Kit and the ENROUTE 0.014 Guidewire are designed to aid in gaining access and delivering interventional devices effectively. Silk Road Medical aims to establish TCAR as the standard of care for carotid artery disease treatment.

PhyFlex Networks is a business services software and broadband access company that creates new business models for cable operators through its True Broadband solution. True Broadband includes a comprehensive software suite for the creation, provisioning, and management of end-to-end broadband services dynamically and on demand.

Elron Ventures is a venture capital firm based in Tel Aviv, Israel, founded in 1962. It specializes in seed and early-stage investments, focusing primarily on sectors such as enterprise software, cybersecurity, and medical technology. The firm is committed to transforming promising ideas into global industry leaders and has a notable history of successful investments and mergers and acquisitions. Elron Ventures has played a significant role in the Israeli innovation landscape, having been a founder and early investor in a variety of companies, including those in healthcare, defense, telecommunications, and medical devices. The firm's investment strategy emphasizes opportunities within Israel, reflecting its dedication to supporting local entrepreneurial talent.

Galil Medical Ltd. specializes in cryotherapy solutions designed to treat a variety of medical conditions, primarily focusing on cancer care. The company offers advanced cryosurgical systems that utilize sub-zero temperatures to destroy diseased tissue through a process known as cryoablation. Key products include the Visual-ICE system, which allows physicians to protect critical anatomy during treatment, and the SeedNet systems, which facilitate minimally invasive procedures for tissue destruction. Galil Medical also provides ultra-thin needles and various accessories, including thermal sensors and prostate procedure templates, to enhance treatment precision. Its technologies are particularly effective for conditions such as kidney, prostate, liver, lung, and breast cancers, as well as for pain management and nerve issues. Founded in 1996 and headquartered in Yokneam, Israel, Galil Medical operates as a subsidiary of BTG plc, with additional offices in Minnesota.

TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that discovers and develops small molecule drugs that modulate programmed cell death pathways to treat debilitating diseases and conditions. The company's Smac Mimetics neutralize critical blocks in the apoptosis pathway to selectively destroy cancer cells. Its Necrostatin drugs block critical steps in the process leading to necrosis, enabling cell survival in a wide range of diseases and injuries where necrosis is a critical component of pathology.

ViaCyte is a preclinical therapeutic company specializing in regenerative medicine therapies for diabetes. Their therapy is based on the differentiation of stem cells into pancreatic beta-cell precursors, with subcutaneous implantation in an encapsulation device. Data in their publications demonstrate that these cells can produce therapeutically relevant levels of insulin in response to blood glucose, and sustain diabetic animals. Their goal is a product which can free both Type 1 and Type 2 patients with diabetes from insulin dependence on a long-term basis, while reducing or eliminating hypoglycemic, microvasculature, and weight-related cardiovascular complications.

Suture Concepts provides solutions for physicians who practice in a cost-conscious environment. They also provide solutions for securing soft tissue to other tissues, the bone, or medical devices.

PhotoThera is currently hiring for the following positions: Sr. Software Engineer Mechanical Engineer Configuration Management Engineer Sr. Electrical Engineer Send your resume and cover letter to ktitano@photothera.com, or go to www.photothera.com for further information. Specialties laser, medical device, eschemic, stroke, infrared

Bayhill Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapeutics for autoimmune diseases. The company uses its therapeutic BHT-DNA platform to develop a pipeline of treatment candidates for autoimmune diseases. Its products in clinical pipeline include BHT-3021, which is in Phase I/II clinical trial for reducing or eliminating the immune system’s attack on the pancreas; BHT-3009, which completed its Phase II trial for the treatment of multiple sclerosis; and BHT-3034, which is in preclinical studies for the treatment of myasthenia gravis. The company was formerly known as Tolerion, Inc. and changed its name to Bayhill Therapeutics, Inc. in November 2002. Bayhill Therapeutics, Inc. was founded in 2000 and is headquartered in Palo Alto, California.

ProteinSimple, part of the Protein Platforms division of Bio-Techne, specializes in innovative protein analysis tools that assist researchers in understanding proteins and their roles in disease. The company offers a diverse range of products, including immunoassay systems for quantifying protein expression and systems designed to assess the structure and purity of protein-based therapeutics. Their nano-proteomic analysis systems focus on resolving protein analysis issues, enabling life science researchers to measure phosphor-protein signaling and activation in small biological samples. These tools allow for the quantification of phosphor-protein isoforms in various cell types, including primary and sorted stem cells, and facilitate the monitoring of drug actions in tissue sections and fine needle aspirates. ProteinSimple's solutions are vital for advancing research in the life sciences globally.

ForteBio is a venture-capital funded life science company developing analytical systems to provide rapid, real-time results for protein quantification or characterization of protein-protein interaction. These systems enable real-time analysis of biomolecular interactions in micro-volume sample sizes, providing information on affinity, kinetics, and concentration.

PhotoThera is currently hiring for the following positions: Sr. Software Engineer Mechanical Engineer Configuration Management Engineer Sr. Electrical Engineer Send your resume and cover letter to ktitano@photothera.com, or go to www.photothera.com for further information. Specialties laser, medical device, eschemic, stroke, infrared

OncoMed Pharmaceuticals is a clinical-stage biopharmaceutical company based in Redwood City, California, specializing in the discovery and development of innovative therapeutics aimed at addressing the biological mechanisms that drive cancer growth, resistance, recurrence, and metastasis. The company is advancing several therapeutic candidates, including Navicixizumab, a bispecific monoclonal antibody targeting Delta-like ligand 4 and vascular endothelial growth factor, which has completed early-phase clinical trials for various solid tumors. Another key candidate, Etigilimab, is an anti-TIGIT monoclonal antibody currently undergoing Phase Ia/b clinical trials for advanced or metastatic solid tumors. OncoMed is also engaged in strategic partnerships aimed at the development of novel small molecule therapeutics and biologics targeting cancer stem cells and the Wnt signaling pathway. Founded in 2004, OncoMed Pharmaceuticals operates as a subsidiary of Mereo BioPharma Group plc.

Bayhill Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapeutics for autoimmune diseases. The company uses its therapeutic BHT-DNA platform to develop a pipeline of treatment candidates for autoimmune diseases. Its products in clinical pipeline include BHT-3021, which is in Phase I/II clinical trial for reducing or eliminating the immune system’s attack on the pancreas; BHT-3009, which completed its Phase II trial for the treatment of multiple sclerosis; and BHT-3034, which is in preclinical studies for the treatment of myasthenia gravis. The company was formerly known as Tolerion, Inc. and changed its name to Bayhill Therapeutics, Inc. in November 2002. Bayhill Therapeutics, Inc. was founded in 2000 and is headquartered in Palo Alto, California.

Velocimed was founded by a group of well known medical entrepreneurs. The company's founders envisioned a company that would become a global leader in the identification and development of innovative technologies with the power to improve the lives of patients whose clinical needs are not being met. Lead by a seasoned management team, Velocimed creates products internally and also looks externally for new technologies by partnering with physicians, inventors and institutions -- particularly those who may lack access to the necessary resources required for early development of new ideas. At Velocimed, they believe that they own a unique position in medical innovation and commercialization. Unlike small incubators, they have the expertise to commercialize viable technology. And unlike large companies, they have the ability to pinpoint opportunities faster and move more quickly.

Vascular Architects, Inc. specializes in designing, developing, manufacturing, and marketing medical devices aimed at treating vascular stenoses, occlusions, and non-vascular obstructions, with a particular focus on peripheral vascular disease. Founded in October 1997 by Dr. Thomas J. Fogarty, a distinguished surgeon and inventor, the company has established itself within the medical device industry by creating innovative surgical products for various markets, including cardiovascular and urology. Vascular Architects develops intraoperative vascular instruments such as Doppler probes and medical oxygen sensors, which are utilized across multiple surgical specialties. The company benefits from the expertise of a highly experienced management team and has engaged key opinion leaders from the interventional and vascular surgery communities to contribute to its Scientific Advisory Board.

PhyFlex Networks is a business services software and broadband access company that creates new business models for cable operators through its True Broadband solution. True Broadband includes a comprehensive software suite for the creation, provisioning, and management of end-to-end broadband services dynamically and on demand.

Bayhill Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapeutics for autoimmune diseases. The company uses its therapeutic BHT-DNA platform to develop a pipeline of treatment candidates for autoimmune diseases. Its products in clinical pipeline include BHT-3021, which is in Phase I/II clinical trial for reducing or eliminating the immune system’s attack on the pancreas; BHT-3009, which completed its Phase II trial for the treatment of multiple sclerosis; and BHT-3034, which is in preclinical studies for the treatment of myasthenia gravis. The company was formerly known as Tolerion, Inc. and changed its name to Bayhill Therapeutics, Inc. in November 2002. Bayhill Therapeutics, Inc. was founded in 2000 and is headquartered in Palo Alto, California.

OsteoBiologics is a biotechnology company. It engages in the development and manufacture of bio-absorbable polymeric scaffolds, films, and related instrumentations for the repair and replacement of bone, soft tissue, and articular cartilage. It provides ACTAEON, a tissue evaluation system, which determines the degree and scope of articular cartilage degeneration. It also manufactures custom parts. OsteoBiologics was founded in 1993 and is headquartered in San Antonio, Texas.

Bacchus Vascular, Inc. is a medical device company based in Santa Clara, California, specializing in the treatment of occlusive vascular disease. Founded in 1999, it develops innovative solutions for interventional radiologists and vascular surgeons in the United States. The company's flagship product, the TRELLIS-8 Peripheral Infusion System, is an isolated thrombolysis catheter designed to facilitate the targeted delivery of clot-dissolving drugs for the treatment of deep vein thrombosis and arterial occlusions. Additionally, Bacchus Vascular focuses on procedures for the percutaneous removal of blood clots from dialysis and peripheral grafts, as well as native arteries and veins, enhancing patient care in the field of vascular interventions.

Velocimed was founded by a group of well known medical entrepreneurs. The company's founders envisioned a company that would become a global leader in the identification and development of innovative technologies with the power to improve the lives of patients whose clinical needs are not being met. Lead by a seasoned management team, Velocimed creates products internally and also looks externally for new technologies by partnering with physicians, inventors and institutions -- particularly those who may lack access to the necessary resources required for early development of new ideas. At Velocimed, they believe that they own a unique position in medical innovation and commercialization. Unlike small incubators, they have the expertise to commercialize viable technology. And unlike large companies, they have the ability to pinpoint opportunities faster and move more quickly.

Vascular Architects, Inc. specializes in designing, developing, manufacturing, and marketing medical devices aimed at treating vascular stenoses, occlusions, and non-vascular obstructions, with a particular focus on peripheral vascular disease. Founded in October 1997 by Dr. Thomas J. Fogarty, a distinguished surgeon and inventor, the company has established itself within the medical device industry by creating innovative surgical products for various markets, including cardiovascular and urology. Vascular Architects develops intraoperative vascular instruments such as Doppler probes and medical oxygen sensors, which are utilized across multiple surgical specialties. The company benefits from the expertise of a highly experienced management team and has engaged key opinion leaders from the interventional and vascular surgery communities to contribute to its Scientific Advisory Board.

PhyFlex Networks is a business services software and broadband access company that creates new business models for cable operators through its True Broadband solution. True Broadband includes a comprehensive software suite for the creation, provisioning, and management of end-to-end broadband services dynamically and on demand.

BioSET, Inc. specializes in the research and development of synthetic bioactive peptides aimed at enhancing bone and soft tissue repair. The company offers a range of medical devices, including AMPLEX, an implantable combination device designed for surgical bone graft applications in spine fusion and other orthopedic procedures. BioSET's product portfolio also includes innovations for sports medicine, peptide signaling molecules, and various scaffold biomaterials, all intended for use in musculoskeletal applications such as trauma, fracture repair, and soft tissue treatments. Founded in 2001 and based in Rockville, Maryland, BioSET operates as a subsidiary of Ferring Pharmaceuticals Inc.

CardioThoracic Systems designs, develops, and manufactures surgical products and systems for minimally invasive cardiac surgery. The Company's current products are designed to enable the majority of cardiothoracic surgeons, using their existing skills coupled with company-sponsored training, to perform MICS on a beating heart. The OPCAB (Off Pump Coronary Artery Bypass) and MIDCAB (Minimally Invasive Direct Coronary Artery Bypass) procedures eliminate the need for a heart-lung machine, and recent studies indicate that the MICS procedures reduce the trauma, procedural costs and post-surgical complications associated with conventional coronary artery bypass graft (CABG) surgery while providing long-term procedural success rates comparable to CABG surgery. CardioThoracic Systems was founded in 1994 and is based in Cupertino, California. As of November 15, 1999, CardioThoracic Systems, Inc. was acquired by Guidant Corp.